Mesothelioma Tests and Biopsy: How the Diagnosis Is Confirmed

Mesothelioma Tests and Biopsy at a Glance

How Tests and Biopsy Fit Into Mesothelioma Diagnosis

Testing typically starts with less invasive evaluations and progresses to tissue sampling if needed. Clinicians review symptoms and exposure history, use imaging to identify abnormalities, may sample an effusion, and select a biopsy method if more tissue is required. Laboratory findings are interpreted alongside clinical and imaging information.

For the full step-by-step pathway, see Mesothelioma Diagnosis. For symptom patterns that may lead to evaluation, see Mesothelioma Symptoms.

Initial Medical Evaluation

Before planning a biopsy, clinicians review the patient’s symptoms, medical history, prior imaging, and possible asbestos exposure. They may examine the chest or abdomen for effusion or other abnormalities. Exposure history may raise suspicion but does not confirm diagnosis.

For risk-factor context, see Mesothelioma Causes.

Imaging Before Biopsy

Imaging helps clinicians locate abnormalities, assess fluid presence, and select safe, informative sampling targets. Chest X-ray is often the initial test. CT defines pleural or abdominal abnormalities. PET/CT assesses active disease and spread. MRI provides detail on local invasion. Ultrasound guides fluid drainage or needle procedures. None of these tests alone can confirm mesothelioma pathologically.

For modality-specific detail, see Imaging Tests.

Can Blood Tests Replace a Biopsy?

No routine blood biomarker can independently confirm or exclude mesothelioma. Markers such as soluble mesothelin-related peptides, osteopontin, and fibulin-3 have been studied, but their accuracy is insufficient to replace imaging and pathology. Liquid-biopsy methods remain investigational and are not standard substitutes for tissue diagnosis.

Fluid Tests and Cytology

Mesothelioma may cause fluid accumulation around the lung, in the abdomen, or, rarely, around the heart. Removing fluid can relieve symptoms and provide cells for laboratory analysis. Pleural-fluid cytology can aid diagnosis in some cases when samples are adequate and interpreted with imaging and ancillary tests, but sensitivity is limited and diagnostic value varies by anatomical site.

Thoracentesis and Pleural Fluid

Thoracentesis removes pleural fluid through a needle or catheter. In patients with suspected pleural mesothelioma and a symptomatic pleural effusion, the 2025 ASCO guideline recommends initial thoracentesis with cytologic examination. The fluid may be processed into a cell block so pathologists can evaluate cellular morphology and, when appropriate, perform immunohistochemistry or selected ancillary studies.

Paracentesis and Peritoneal Fluid

Paracentesis removes ascitic fluid from the abdomen and may help relieve symptoms. Although the fluid can be examined cytologically, current peritoneal-mesothelioma consensus guidance discourages relying on ascitic-fluid cytology for diagnosis because it often provides insufficient material and does not preserve tissue architecture. Tissue confirmation is preferred; when feasible, laparoscopy is favored over image-guided core biopsy because it can also help assess intra-abdominal disease distribution and surgical candidacy.

See the dedicated Peritoneal Mesothelioma guide for site-specific context.

Pericardial Fluid Sampling

Primary pericardial mesothelioma is exceptionally rare. Pericardiocentesis may be performed to manage significant effusion and obtain material for analysis. A nondiagnostic fluid sample does not exclude pericardial mesothelioma, and no standardized diagnostic algorithm exists for this site.

See Pericardial Mesothelioma.

Why Tissue Biopsy Matters

A tissue biopsy provides tissue architecture and cellular material for microscopic examination. Adequate material helps pathologists confirm malignancy, distinguish mesothelioma from similar cancers, identify histologic subtype, and perform additional studies as needed. Small samples may not capture the full pattern of a heterogeneous tumor.

Thoracoscopy and Pleural Biopsy

Thoracoscopy allows direct inspection of the pleural space and collection of multiple biopsies from abnormal pleura. For patients with suspected pleural mesothelioma in whom antineoplastic treatment is planned, the 2025 ASCO guideline strongly recommends thoracoscopic biopsy because it can provide histologic confirmation, improve subtype assessment, contribute staging information, and preserve material for additional studies.

For pleural-site context, see Pleural Mesothelioma.

Medical Thoracoscopy / Pleuroscopy vs VATS

“Thoracoscopy” is a broad term, and procedures differ. Medical thoracoscopy, or pleuroscopy, is usually performed by a respiratory specialist with local anesthesia and sedation. Video-assisted thoracoscopic surgery (VATS) is a surgical approach under general anesthesia. Both provide pleural tissue; the choice depends on expertise, clinical needs, and patient condition. Neither is universally superior.

Core Needle Biopsy vs Fine-Needle Aspiration

Image-guided core needle biopsy uses a hollow needle to remove one or more small cylinders of tissue. It can be useful for accessible pleural, chest-wall, or abdominal lesions, particularly when thoracoscopy or open pleural biopsy is not suitable. ASCO specifically recommends core needle biopsy of an accessible lesion in selected patients who are not candidates for thoracoscopic or open pleural biopsy and who have a nondiagnostic thoracentesis or no pleural effusion.

Fine-needle aspiration (FNA) uses a thinner needle and typically yields cells or a small amount of material, not a tissue core. FNA may aid diagnosis in select cases but is not equivalent to core biopsy. When tissue architecture, invasion, subtype, or further testing is needed, a larger, well-preserved sample is preferred.

Open or Surgical Biopsy

Open biopsy is not a routine first-line procedure. For suspected pleural mesothelioma when antineoplastic treatment is planned, ASCO conditionally recommends open pleural biopsy if tumor extent prevents a thoracoscopic approach. Clinicians aim to obtain adequate tissue while minimizing unnecessary procedures.

Laparoscopy and Peritoneal Biopsy

When peritoneal mesothelioma is suspected, current consensus guidance prefers laparoscopic tissue biopsy when feasible because it allows direct inspection, targeted sampling, and assessment of intra-abdominal disease distribution. Image-guided core biopsy may be used in selected situations when laparoscopy is not appropriate or safe. The peritoneal approach should be considered separately from pleural mesothelioma rather than defaulting to thoracic recommendations.

Biopsy for Rare Mesothelioma Sites

Pericardial mesothelioma

Because primary pericardial mesothelioma is exceptionally rare, tissue acquisition is individualized. Imaging and pericardial-fluid analysis may raise suspicion, but diagnosis often relies on pathologic examination of tissue from biopsy or surgery when feasible. Evidence is too limited to support a universal biopsy algorithm.

Mesothelioma of the tunica vaginalis

Mesothelioma of the tunica vaginalis is a rare tumor of the serosal lining around the testis, distinct from typical testicular cancer. It may present with a hydrocele or paratesticular/scrotal mass. Ultrasound can detect abnormalities, but diagnosis is usually made by examining tissue from the hydrocele sac or surgical specimen. Most evidence comes from case reports and series, so no standard biopsy pathway is established.

For the four anatomical sites, see Types of Mesothelioma.

How Doctors Choose a Biopsy Method

The clinical team considers tumor location, presence of effusion, safe access to the lesion, expected tissue yield, patient cardiopulmonary health, and whether histologic subtype or further studies are needed. The least invasive procedure is not always best if it cannot provide an adequate sample, and the most invasive is not always necessary if a lower-risk approach suffices.

Preparing for a Biopsy

Preparation depends on the procedure. The care team may review blood counts, bleeding risk, allergies, kidney function if contrast is used, and medications affecting clotting. Some procedures require fasting or sedation; others do not. Patients should follow instructions from their treating team rather than using generic biopsy guidelines.

What Happens During a Biopsy?

Details vary by technique. Image-guided needle procedures use local anesthetic and CT or ultrasound guidance. Medical thoracoscopy uses local anesthesia with sedation; VATS uses general anesthesia. Laparoscopy is a surgical procedure. The team monitors the patient and uses sterile technique to obtain sufficient material for pathology.

Biopsy Risks and Recovery

Potential risks vary by procedure and may include pain, bleeding, infection, pneumothorax (for chest procedures), reactions to sedation or anesthesia, and injury to nearby structures. These complications are not inevitable, and their likelihood depends on the procedure, target location, and patient health. The treating team will explain relevant risks before consent.

Recovery time also varies. Some needle procedures require only brief observation, while thoracoscopic or surgical procedures may need longer monitoring or hospitalization. There is no universal recovery time for mesothelioma biopsies.

What Happens to the Tissue Sample?

The specimen is sent to pathology, where tissue is processed and examined microscopically. The pathologist evaluates morphology and may order immunohistochemical stains to confirm mesothelial lineage and distinguish mesothelioma from other tumors. Additional tests may be used if the distinction between malignant and reactive mesothelial proliferation is unclear or more information is needed.

Why Sample Adequacy Matters

Mesothelioma is classified as epithelioid, sarcomatoid, or biphasic. Biphasic tumors have both components, so small samples may not reflect tumor heterogeneity. Adequate tissue is also important for assessing invasion, performing IHC panels, and preserving material for ancillary studies or future testing.

How Pathologists Confirm Mesothelioma

Pathologists do not diagnose mesothelioma based on a single stain. They integrate tissue architecture, cell morphology, anatomical site, imaging findings, and an immunohistochemical panel tailored to the differential diagnosis. Examples of markers that can support mesothelial lineage include calretinin, WT1, D2-40, and CK5/6, while other markers help evaluate alternative diagnoses such as metastatic carcinoma. The exact panel varies with anatomical site, morphology, and the differential diagnosis.

BAP1, MTAP and CDKN2A/FISH

Current International Mesothelioma Interest Group guidance includes ancillary tools such as BAP1 and MTAP immunohistochemistry and FISH for CDKN2A homozygous deletion. In an appropriate mesothelial context, loss of BAP1 or MTAP expression and/or homozygous CDKN2A deletion can strongly support malignancy. However, retained BAP1 or MTAP expression or absence of CDKN2A homozygous deletion does not exclude mesothelioma; test performance varies by anatomical site and histologic subtype.

Understanding the Biopsy Report

A pathology report may include the anatomical site, specimen type, diagnosis, histologic subtype, and immunohistochemical findings. Some reports also mention tumor grade, invasion, or molecular results. If terms like “atypical mesothelial proliferation,” “suspicious,” “cannot exclude,” or “insufficient for definitive classification” appear, the care team can advise if more tissue, additional stains, or expert review is needed.

When a Second Pathology Review May Help

Mesothelioma can be difficult to distinguish from reactive changes and other cancers, especially with small or unusual samples. A second review by an experienced pathologist can be helpful in challenging cases. This does not imply that all initial pathology interpretations are unreliable.

Patients can ask how to obtain their pathology report, slides, and imaging if another center will review the case. See Find a Mesothelioma Specialist.

Can a Biopsy Spread Mesothelioma?

Procedure-tract metastasis can occur after pleural interventions in pleural mesothelioma. Current ASCO guidance recommends that prophylactic irradiation of intervention tracts generally not be offered solely to prevent tract recurrences. Large phase III trials likewise did not show a clear primary-endpoint benefit from routine prophylactic radiotherapy. Procedure planning and follow-up are individualized.

What Happens After the Biopsy?

Pathology results are integrated with imaging and clinical evaluation. If mesothelioma is confirmed, the team assesses disease extent and discusses treatment options. Final report timing varies, as some cases require additional stains, ancillary tests, or specialist review. A fixed turnaround time cannot be guaranteed.

Continue with Mesothelioma Stages, Mesothelioma Treatment and Mesothelioma Prognosis.

Questions to Ask Before a Mesothelioma Biopsy

1. What finding are you trying to confirm or rule out with this procedure?
2. Why is this sampling method preferred in my situation?
3. Will the sample be large enough for histologic subtype, immunohistochemistry, and any additional tests that may be needed?
4. What type of anesthesia or sedation is planned?
5. Which medications should I continue, and are there any that the procedure team wants me to hold?
6. What are the most relevant risks for this specific procedure?
7. How long will I be observed afterward, and what symptoms should prompt urgent contact with the care team?
8. If the sample is nondiagnostic, what would the next step be?
9. Will the pathology be reviewed by someone experienced in mesothelioma if the diagnosis is difficult?

Frequently Asked Questions

References

1. National Cancer Institute. Mesothelioma Diagnosis & Prognosis. Updated May 16, 2025. View source.
2. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006–1038. PMID: 39778125. doi:10.1200/JCO-24-02425.
3. Husain AN, Chapel DB, Attanoos R, et al. Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group. Archives of Pathology & Laboratory Medicine. 2024;148(11):1251–1271. PMID: 38586983. doi:10.5858/arpa.2023-0304-RA.
4. Brown LM, Wilkins SG, Bansal VV, et al. Consensus Guideline for the Management of Peritoneal Mesothelioma. Annals of Surgical Oncology. 2026;33(6):5125–5141. PMID: 40560500. doi:10.1245/s10434-025-17358-x.
5. McGehee E, Gerber DE, Reisch J, Dowell JE. Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases. Clinical Lung Cancer. 2019;20(2):e152–e157. PMID: 30594459. doi:10.1016/j.cllc.2018.11.008.
6. Grogg JB, Fronzaroli JN, Oliveira P, et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. Journal of Cancer Research and Clinical Oncology. 2021;147(9):2671–2679. PMID: 33559739. doi:10.1007/s00432-021-03533-6.
7. Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncology. 2016;17(8):1094–1104. PMID: 27345639. doi:10.1016/S1470-2045(16)30095-X.
8. Bayman N, Appel W, Ashcroft L, et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. Journal of Clinical Oncology. 2019;37(14):1200–1208. PMID: 30920878. doi:10.1200/JCO.18.01678.
9. Hollevoet K, Reitsma JB, Creaney J, et al. Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. Journal of Clinical Oncology. 2012;30(13):1541–1549. PMID: 22412141. doi:10.1200/JCO.2011.39.6671.